Midatech Pharma Plc (LOM:MTPH, NASDAQ:MTP) said it had received £450,000 under the terms of its contract with Emergex Vaccines.
The latter is using the former’s gold nanoparticle platform to develop of vaccines for flu, meningitis, bacterial pneumonia, Ebola and a number of other infectious diseases. This is the first deployment of the technology in this setting.
"I am pleased to see progress being made in the adaptation of our gold nanoparticle technology for use in vaccines for infectious disease,” said chief executive Jim Phillips.
“[This] perfectly complements our type 1 diabetes collaboration in antigen specific immunotherapy, and our early-stage internal programs which address auto-immune disease and immuno-oncology."